Drug Pricing Law Linked to Oncology Research Drop
A study associates the Inflation Reduction Act with reduced follow-on small-molecule oncology trials and approvals.
Updated on Nov. 9, 2026 in Cancer
Live Poll
Should Congress change Medicare drug price rules so new pills aren't discouraged?
Vital Transformation research published October 20 finds the Inflation Reduction Act is associated with a 37% decline in follow-on small-molecule oncology studies and a 27% decline in lead-indication small molecule approvals.
Why it matters
The findings suggest Medicare drug price negotiation rules may shape which cancer treatments companies choose to pursue, with small molecule drugs facing a shorter protection window than biologics. Small molecules make up about 90% of prescription drugs, so the pattern could affect a large share of the treatment pipeline.
The analysis covered 1,148 secondary clinical trials tied to 364 FDA-approved medicines from 175 companies between 2018 and 2025, and the 37% and 27% declines are associations rather than established causes. It remains unclear from the study whether the drop reflects lasting shifts in research investment or a temporary adjustment.
The players
Vital Transformation
Vital Transformation is the research organization that conducted the analysis of oncology drug development following the Inflation Reduction Act.
Centers for Medicare & Medicaid Services
The Centers for Medicare & Medicaid Services is the federal agency that administers Medicare and carries out drug price negotiations under the Inflation Reduction Act.
The details
The Inflation Reduction Act allows the Centers for Medicare & Medicaid Services to negotiate drug prices, and small molecule drugs receive a maximum of nine years of protection from those negotiations while biologics are exempt for as long as 13 years. Drugs approved for an additional indication do not receive extra protection, and approximately 60-75% of marketed oncology medications have more than one indication.
Timeline
2018 to 2025: period covered by the analyzed FDA-approved medicine trials.
Oct. 20: Vital Transformation study published.
Nov. 9, 2026: article published.
Big Picture
The findings follow the Inflation Reduction Act's Medicare drug-price negotiation provisions, which set a nine-year protection window for small molecule drugs compared with 13 years for biologics. The study connects that asymmetry to a measured decline in small-molecule oncology research.
For patients, the trend could mean fewer new small molecule cancer treatments reaching the market over time, depending on how the decline develops. Readers following cancer drug access may watch how Medicare negotiation rules shape which therapies companies pursue.
The takeaway
Drug pricing policy and cancer drug development are closely linked, and the protection periods set for different drug types may influence which treatments reach patients. Following future research on approval trends can help show whether the observed declines continue.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Bio.
Live Poll
Should Congress change Medicare drug price rules so new pills aren't discouraged?
